{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}], "size": 11, "snippet": "has the meaning set forth in the Preamble.", "samples": [{"hash": "eVV8nonaNvJ", "uri": "/contracts/eVV8nonaNvJ#gilead", "label": "Option and License Agreement (Agenus Inc)", "score": 30.2073917389, "published": true}, {"hash": "32pDZuR3QbP", "uri": "/contracts/32pDZuR3QbP#gilead", "label": "License Agreement (Agenus Inc)", "score": 30.2073917389, "published": true}, {"hash": "1F2Oqmbcbbe", "uri": "/contracts/1F2Oqmbcbbe#gilead", "label": "Option and License Agreement (Agenus Inc)", "score": 30.2073917389, "published": true}], "hash": "8bc994fbf8747c57816edd3723d39ac7", "id": 1}, {"snippet_links": [{"key": "opening-paragraph", "type": "clause", "offset": [50, 67]}, {"key": "this-agreement", "type": "clause", "offset": [71, 85]}], "size": 8, "snippet": "shall have the meaning set forth in the first and opening paragraph of this Agreement.", "samples": [{"hash": "a2k40dq4tuE", "uri": "/contracts/a2k40dq4tuE#gilead", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 33.1615333557, "published": true}, {"hash": "9fLy2LKWdcf", "uri": "/contracts/9fLy2LKWdcf#gilead", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 32.2087593079, "published": true}, {"hash": "5ndDYSQGzbc", "uri": "/contracts/5ndDYSQGzbc#gilead", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 31.2121829987, "published": true}], "hash": "cd6c859a0854631dcafcf42a945c0a40", "id": 2}, {"snippet_links": [{"key": "delaware-corporation", "type": "clause", "offset": [31, 51]}, {"key": "principal-offices", "type": "definition", "offset": [61, 78]}], "size": 7, "snippet": "means Gilead Sciences, Inc., a Delaware corporation with its principal offices located at \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587.", "samples": [{"hash": "i4Qt9gzc0b1", "uri": "/contracts/i4Qt9gzc0b1#gilead", "label": "Collaboration and License Agreement (ARCA Biopharma, Inc.)", "score": 21.6050643921, "published": true}, {"hash": "dzc5pm6it9Q", "uri": "/contracts/dzc5pm6it9Q#gilead", "label": "Collaboration and License Agreement (Nuvelo Inc)", "score": 21.0, "published": true}, {"hash": "dhQWaH9BWZw", "uri": "/contracts/dhQWaH9BWZw#gilead", "label": "Collaboration Agreement (Nuvelo Inc)", "score": 21.0, "published": true}], "hash": "4343dccb82de2fd0027b13057ff3a014", "id": 3}, {"snippet_links": [], "size": 5, "snippet": "Gilead shall mean Gilead Sciences, Inc.", "samples": [{"hash": "5karywOejrF", "uri": "/contracts/5karywOejrF#gilead", "label": "Divestiture Agreement (Ophthotech Corp.)", "score": 24.6194381714, "published": true}, {"hash": "75g5NoUea1f", "uri": "/contracts/75g5NoUea1f#gilead", "label": "Research and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}, {"hash": "5ykWD9RkUgN", "uri": "/contracts/5ykWD9RkUgN#gilead", "label": "Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}], "hash": "c8a0b7525399cb24226f38295ce59e30", "id": 4}, {"snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [36, 48]}], "size": 5, "snippet": "shall have the meaning set forth in the preamble hereto.", "samples": [{"hash": "8f4K3QcPzL1", "uri": "/contracts/8f4K3QcPzL1#gilead", "label": "Collaboration Agreement (Gilead Sciences Inc)", "score": 26.1498966217, "published": true}, {"hash": "ggDHrbDOXwL", "uri": "/contracts/ggDHrbDOXwL#gilead", "label": "License and Collaboration Agreement (Gilead Sciences Inc)", "score": 20.0, "published": true}], "hash": "28960b95fcba0d7e9fb0f901aaa2499d", "id": 5}, {"snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}, {"key": "to-this-agreement", "type": "clause", "offset": [42, 59]}], "size": 3, "snippet": "has the meaning set forth in the preamble to this Agreement.", "samples": [{"hash": "4zVhRXaw2CY", "uri": "/contracts/4zVhRXaw2CY#gilead", "label": "License and Collaboration Agreement (Galapagos Nv)", "score": 30.6563987732, "published": true}, {"hash": "6z16P057QkY", "uri": "/contracts/6z16P057QkY#gilead", "label": "License and Collaboration Agreement (Galapagos Nv)", "score": 27.0479125977, "published": true}], "hash": "1f3de82c531442eb5b3bb26b80892c0d", "id": 6}, {"snippet_links": [{"key": "formulation-technology", "type": "clause", "offset": [39, 61]}, {"key": "the-company", "type": "definition", "offset": [87, 98]}, {"key": "to-pay", "type": "clause", "offset": [115, 121]}, {"key": "gilead-technology", "type": "definition", "offset": [161, 178]}, {"key": "access-to-the", "type": "clause", "offset": [242, 255]}, {"key": "the-final", "type": "clause", "offset": [270, 279]}, {"key": "drug-product", "type": "clause", "offset": [291, 303]}], "size": 2, "snippet": ") using Gilead's proprietary liposomal formulation technology (\"Gilead's Technology\"). The Company may be required to pay a royalty to Gilead for the use of the Gilead Technology, but such requirement will not prevent the Company's exclusive access to the Lead Drug and the final formulated drug product.", "samples": [{"hash": "hlhhyCkEJGZ", "uri": "/contracts/hlhhyCkEJGZ#gilead", "label": "Securities Purchase Agreement (Miravant Medical Technologies)", "score": 18.0, "published": true}, {"hash": "b4TSGdZXHeu", "uri": "/contracts/b4TSGdZXHeu#gilead", "label": "Securities Purchase Agreement (Miravant Medical Technologies)", "score": 18.0, "published": true}], "hash": "f38cb6838826d94fae4ac8d266aa3483", "id": 7}, {"snippet_links": [{"key": "standard-api", "type": "definition", "offset": [9, 21]}, {"key": "given-year", "type": "definition", "offset": [62, 72]}, {"key": "in-accordance-with", "type": "clause", "offset": [97, 115]}, {"key": "section-47", "type": "clause", "offset": [116, 127]}], "size": 2, "snippet": "s Actual Standard API Costs\u201d shall mean, for a given API in a given Year, the amount established in accordance with Section 4.7.", "samples": [{"hash": "g1JxMFzkBZi", "uri": "https://investors.gilead.com/static-files/bcc07069-7739-457b-a71e-21375ba5cf77", "label": "investors.gilead.com", "score": 9.965092659, "published": false}, {"hash": "lRg903L45Bl", "uri": "https://truecostofhealthcare.org/wp-content/uploads/2015/01/GileadSciences_10K_20040311.8885020.pdf", "label": "truecostofhealthcare.org", "score": 7.1204652786, "published": false}], "hash": "e1bbd863ab11f9a3a948d62b2bc6104f", "id": 8}, {"snippet_links": [{"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [26, 64]}, {"key": "incorporated-by-reference", "type": "clause", "offset": [69, 94]}, {"key": "registration-statement", "type": "definition", "offset": [105, 127]}], "size": 2, "snippet": "or the \u201cRegistrant\u201d) with the Securities and Exchange Commission are incorporated by reference into this Registration Statement:", "samples": [{"hash": "csxq2Hosef6", "uri": "/contracts/csxq2Hosef6#gilead", "label": "Option Agreement", "score": 23.9650917053, "published": true}, {"hash": "6eSYpJmysVN", "uri": "/contracts/6eSYpJmysVN#gilead", "label": "Option Agreement", "score": 23.4859676361, "published": true}], "hash": "2ec0a8aaed2654418cb63a64cad0538f", "id": 9}, {"snippet_links": [], "size": 1, "snippet": "means Gilead Sciences, Inc.;", "samples": [{"hash": "9knnDWtCXba", "uri": "https://ir.tangotx.com/static-files/22565a32-e8a2-4c74-863b-bfe7a50d5fbf", "label": "ir.tangotx.com", "score": 12.0773439407, "published": false}], "hash": "24366767d35f779dee0b72a5603a597d", "id": 10}], "next_curs": "ClMSTWoVc35sYXdpbnNpZGVyY29udHJhY3Rzci8LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIPZ2lsZWFkIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Gilead", "size": 53, "snippet": "has the meaning set forth in the Preamble.", "id": "gilead", "examples": ["Borrower (a) shall not, without the consent of Agent, amend or terminate the <strong>Gilead</strong> Collaboration Agreement, Taiho Agreement or any other Material Agreements with <strong>Gilead</strong> in a manner that is reasonably likely to have a material negative impact on Agent or Lenders and (b) shall give prompt written notice to the Agent of entering into a Material Agreement or materially amending or terminating a Material Agreement."], "related": [["novartis", "Novartis", "Novartis"], ["bms", "BMS", "BMS"], ["merck", "Merck", "Merck"], ["pfizer", "Pfizer", "Pfizer"], ["lilly", "Lilly", "Lilly"]], "related_snippets": [], "updated": "2026-02-28T06:15:34+00:00"}, "json": true, "cursor": ""}}